ARTICLE | Company News
Debiopharm S.A., Ipsen deal
September 14, 2009 7:00 AM UTC
Ipsen granted Debiopharm an exclusive, worldwide license to Debio 0931 (formerly IRC-083864) to treat cancer. The cell division cycle 25C ( CDC25C, CDC25) inhibitor is in preclinical testing. Debiop...